SCHEMBL26485808

SCHEMBL26485808

C#CC1(Nc2nc(=O)n(-c3cccnc3)c3nc(C(F)(F)F)ccc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 19/20 0.50
▸ CCR9 P51686 1/20 0.34
▸ PRMT5 O14744 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31026798 0.86 MAT2A (0.37) MAT2ACCR9PRMT5
SCHEMBL26489468 0.86 MAT2A (0.37) MAT2ACCR9PRMT5
SCHEMBL26489377 0.84 MAT2A (0.46) MAT2APRMT5
SCHEMBL26485812 0.84 MAT2A (0.45) MAT2A
SCHEMBL26485807 0.83 MAT2A (0.48) MAT2APRMT5
SCHEMBL26485714 0.82 MAT2A (0.55) MAT2APRMT5
SCHEMBL22103120 0.81 MAT2A (0.75) MAT2A
SCHEMBL26485646 0.79 MAT2A (0.39) MAT2ACCR9PRMT5
SCHEMBL30420090 0.78 MAT2A (0.67) MAT2APRMT5
SCHEMBL26484971 0.78 MAT2A (0.67) MAT2APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042890-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2025-02-06 — — US disclosed
CN-118434722-A Methionine adenosyltransferase 2A (MAT 2A) inhibitors and uses thereof 英矽智能科技知识产权有限公司 2024-08-02 — — CN disclosed
US-11999713-B2 Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2024-06-04 — — US disclosed
US-20240132465-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE LTD. (CN) 2024-04-25 — — US disclosed
WO-2023066283-A1 METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999713-B2 Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof MAT2A, MAT2B, MAT1A MAT2A 1/4885CCR9 4865/4885PRMT5 48/4885
US-20250042890-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF MAT2A, MAT2B, MAT1A MAT2A 1/4885CCR9 4865/4885PRMT5 48/4885
US-20240132465-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF MAT2A, MAT2B, MAT1A MAT2A 1/4885CCR9 4865/4885PRMT5 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback